Copy Link Print Information

Q-VD-OPh

(Synonyms: QVD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone)
108 Cited Publications
Customer Review

Based on 108 publication(s) in Google Scholar

Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.

For research use only. We do not sell to patients.

  • Purity: 99.90%
  • CAS No.: 1135695-98-5
  • Formula: C26H25F2N3O6
  • Molecular Weight:513.49
  • Storage:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Q-VD-OPh Chemical Structure
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Q-VD-OPh Chemical Structure
    Q-VD-OPh Chemical Structure
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
  • Experimental Validation Results for Q-VD-OPh
CAS No.: 1135695-98-5
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Q-VD-OPh:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Q-VD-OPh

More
Customer Validation & Images
WBCell Proliferation/Viability AssayApoptosis AnalysisRT-PCR
  • WB
  • RT-PCR
  • RT-PCR
  • WB
  • Cell Proliferation/Viability Assay
  • Apoptosis Analysis
  • RT-PCR
  • WB

All Caspase Isoforms

More

All HIV Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Q-VD-OPh Chemical Structure
    Q-VD-OPh Chemical Structure
    1/16
  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Nature. 2025 Apr;640(8060):1062-1071. [Abstract]

    Customer Validation
     Control or VDAC2-deficient B16-OVA tumour cells were treated with or without IFNγ (in the presence of the pan caspase inhibitor Q-VD-Oph (40 μM, 24 h) to inhibit cell death of VDAC2-deficient cells) for 24 h, or control cells were treated with ABT-737 (BCL-2 inhibitor) + S63845 (MCL-1 inhibitor) + Q-VD-OPh (pan-caspase inhibitor) (A + S group) for 6 h.

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     RT-qPCR for p53 target genes in two independent isogenic non-targeting sgRNA control (NTC) and Trp53 KO Eμ-Myc lymphoma cell lines pre-treated with QVD-O-Ph (25 mM, 15 min), then S63845 for indicated time points. Fold change is relative to 0 h for each cell line.

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     RTqPCR for the p53 target genes PUMA and P21 in parental DOHH2 and two independently derived Rho0 cell lines. Cells were pre-treated with the caspase inhibitor QVD-O-Ph (HY-12305), and then treated with 100 nM S63845 for 24 h or, as a comparator for potent p53 activation, treated with 10 µM of the MDM2 inhibitor Nutlin-3a (HY-10029) for 24 h. Ct values for each gene are normalized to the housekeeping gene HMBS, and fold change is shown relative to the DMSO-treated parental cell sample. Error bars represent S.E.M. for two independent experiments.

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     Immunoblotting for p53 and PUMA in parental DOHH2 lymphoma cells and two independently derived Rho0 cell lines. Cells were pre-treated with QVD-O-Ph (HY-12305), and then treated with 100 nM S63845 or, as a control for potent p53 stabilization, treated with 10 µM Nutlin-3a (HY-10029) for 24 h. Blotting for HSP70 was used as a loading control. Representative blot shown from three independent experiments. Quantifications of p53 protein levels from three independent immunoblotting experiments are shown, relative to HSP70. Error bars represent S.D.

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Nature. 2023 Mar;615(7950):158-167. [Abstract]

    Customer Validation
     Cell viability assessment in Tbk1-null B16 cells pre-treated with RIPK3 inhibitor (HS-1371, 2 μM) or MLKL inhibitor (GW806742X, 5 μM) and the pan-caspase inhibitor Q-VD-Oph (20 μM) +/− TNFα/IFNγ for 9 days (n=6, 2 independent experiments: 2-way ANOVA, Dunnett’s multiple comparisons test).

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2022 Aug;29(8):1486-1499. [Abstract]

    Customer Validation
     Flow cytometry of CD4 and CD8 T cells expressing caspase activity in the absence (Med) or presence of Q-VD-Oph (Q-VD) (10 μM) (Top). Inhibition of caspase activity (preventive effect) in the presence of IDN-6556 (10 μM), VX-765 (10 μM), Q-VD and MCC950. Percentages were calculated as follows: (Med-Inh/Med)*100. Each dot represents one individual (Middle). Flow cytometry of CD4 and CD8 T cells expressing annexin V in the absence (Med) or presence of Q-VD (Bottom).

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2021 May;18(5):1186-1196. [Abstract]

    Customer Validation
     Control and VDAC1-deficient MLFs (1×106) were stimulated with Q-VD-OPh (A/Q) (10 μM each), infected with HSV-1 or EMCV (MOI=1) for 6h prior to qPCR analysis of the indicated genes. The data shown are the mean±SD from one representative experiment performed in triplicate. ns nonsignificant; *P < 0.05; ***P < 0.001 (unpaired t-test)

  • 1/16

    Q-VD-OPh purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2019 May;110(5):1746-1759. [Abstract]

    Customer Validation
     Cells are treated with RA in the presence or absence of the caspase inhibitor Q-VD-OPh, and cleaved caspase-3 and caspase-8 and total and cleaved PARP were analyzed.

  • Q-VD-OPh